2015 Was a Record Breaking Year for Horizon Pharma Sample Clauses


2015 Was a Record Breaking Year for Horizon Pharma. Exceptional Financial Results; Achieved Clinical and M&A Milestones Guidance of $750 to $760mm in 2015 net sales (1) More than DOUBLE 2014 net sales Guidance of $350 to $360mm in 2015 adjusted EBITDA (1) More than TRIPLE 2014 adjusted EBITDA Initiated ACTIMMUNE Phase 3 trial in Friedreich’s ataxia (FA) and Phase 1 trial in cancer Expect FA data December 2016 $500mm to $1bn peak net sales opportunity Received European regulatory approval for RAVICTI Expect commercial launch in 2017 Acquired Hyperion (RAVICTI/BUPHENYL) and Announced Crealta (KRYSTEXXA) acquisition Hyperion expected to generate $100mm in 2016 adjusted EBITDA; Crealta expected to add $45 to $50mm in adjusted EBITDA in 1st year post-close (1) Represents financial guidance issued on Nov. 6, 2015. By this presentation Horizon is not updating or confirming the prior guidance. 6 Focused Development Pipeline ACTIMMUNE FA and RAVICTI (two months—two years) Key Financial Upside